6 / 10
Page 22
Notes:
conferenceseries
.com
Volume 08
Journal of Alzheimers Disease & Parkinsonism
Alzheimer's Congress 2018
May 30-31, 2018
May 30-31, 2018 Osaka, Japan
10
th
World Congress on
Alzheimer's Disease & Dementia
Neurotropin inhibits neuroinflmmation via suppressing NF-κB and MAPKs signaling pathways in
lipopolysaccharide-stimulated BV2 cells
Yuqiu Zheng
Sun Yat-sen University, China
N
euroinflammtion plays an important role in several neurological diseases, especially in Alzheimer’s Disease (AD).
Neurotropin (NTP) is a widely used drug in China and Japan mainly for the treatment of chronic pain and peripheral
inflammationandprevious studies have indicated thatNTPcould improve cognitive impairment inAPP/PS1miceby stimulating
the production of BDNF and suppressing the oxidative stress. Nevertheless, the effects of NTP on neuroinflammation have
not been explored. In this study, we investigated the anti-inflammatory effects of NTP in lipopolysaccharide (LPS)-stimulated
BV-2 microglial cells and its underlying mechanisms. BV-2 cells were pretreated with NTP for 12 h before exposure to LPS. The
expression of pro-inflammatory cytokines (TNF-α and IL-6) were detected by RT-PCR and EILSA at mRNA and protein levels,
respectively. Western blotting was conducted to measure the protein levels of major genes in MAPKs and NF-κB signaling
pathways. Results demonstrated that NTP could attenuate the production of pro-inflammatory cytokines. Furthermore, NTP
inhibited the activation of NF-κB signaling by decreasing the translocation of NF-κB p65 to the nucleus and suppressed the
MAPKs signaling pathway via inhibition of the phosphorylation of p38, ERK and JNK. Taken together, these findings suggest
that NTP exerts anti-inflammatory effects by suppressing the production of pro-inflammatory mediators via inhibition of
NF-κB and MAPKs signaling pathways in LPS-stimulated BV-2 cells, indicating that NTP might be a potential choice for the
treatment of neuroinflammation.
Biography
Yuqiu Zheng has received her Bachelor’s degree in Clinical Medicine from Sun Yat-sen University and presently pursuing her Master’s degree in Neurology in
Sun-Yat-sen Memorial Hospital, Sun Yat-sen University. She has been investigating the pathologies and therapeutics of Alzheimer’s disease, especially novel drug
Yuqiu Zheng, J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C4-045